Du är nu på väg att lämna en GSK-hemsida

Denna länk leder till en hemsida som inte tillhör GSK. GSK tar inget ansvar för innehållet på tredje parts hemsidor.

Fortsätt

Tillbaka

Nucala

Product menu

Pick section Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Severe Eosinophilic Asthma (SEA)

NA

Proven and tested in eosinophilic disease3

Help your patients with recurrent nasal polyps today with Nucala1

Nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP (Chronic Rhinosinusitis with Nasal Polyps) for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.3

Nsala polyp size
Nasal obstruction
Surgery
QoL

In the SYNAPSE study, all primary and secondary endpoints were met with statistical significance.1

  • * Co-primary endpoints:

    Improvement in nasal polyp size. Mean (SD) change from baseline in total endoscopic nasal polyp score at Week 52: NUCALA + SOC** (n=206), -0.9 (1.90) (baseline score: 5.4) vs placebo + SOC** (n=201), -0.1(1.46) (baseline score: 5.6); P<0.0001.1,2

    Improvement in nasal obstruction. Mean (SD) change from baseline in nasal obstruction VAS score at Weeks 49-52: NUCALA + SOC** (n=206), -4.2 (3.42) (baseline score: 8.9) vs placebo + SOC** (n=201), -2.5 (3.15) (baseline score: 9.0); P<0.0001.1,2

  • † Secondary endpoints:

    Improvement in need for surgery. Time to next nasal polyp surgery up to Week 52: 57% reduction in the proportion of patients who had surgery with NUCALA + SOC** vs placebo + SOC**, HR: 0.43, 95% CI: 0.25-0.76; p=0.0032. Nucala: n=18/206; placebo: n=46/201.1

    Improvement in quality of life. Median change from baseline in SNOT-22 total score at Week 52;
    NUCALA + SOC**, 30-point improvement vs placebo + SOC**, 14-point improvement; P=0.0032.1

SELECTED SAFETY INFORMATION

Warnings/Precautions: Should not be used to treat acute asthma exacerbations. Patients should be instructed to seek medical advice if their asthma remains uncontrolled or worsens after starting treatment. Abrupt discontinuation of corticosteroids after initiation of mepolizumab treatment is not recommended.

Allergic reactions: Acute and delayed systemic reactions, including hypersensitivity reactions, have occurred following administration of mepolizumab. Patients should be instructed to seek medical attention immediately if allergic reactions occur. In the event of a hypersensitivity reaction, appropriate treatment as clinically indicated should be initiated.

Parasitic infections: Pre-existing helminth infections should be treated before starting therapy. If patients become infected whilst receiving treatment with mepolizumab and do not respond to anti-helminth treatment, temporary discontinuation of therapy should be considered.

Organ-threatening or life-threatening manifestations of EGPA and HES: Has not been studied.

Adverse reactions: In clinical studies in patients with severe refractory eosinophilic asthma and EGPA, headache, injection site reactions and back pain were the most commonly reported adverse reactions during treatment. In patients with CRSwNP: Headache and back pain. In patients with HES: Headache, urinary tract infection, injection site reactions and pyrexia.

Nucala is a once-monthly biologic with a fixed-dose treatment for your patients with nasal polyps

The recommended dose of mepolizumab is 100 mg administered SC once every 4 weeks.3

Nucala Pen
At Home

AT HOME
PRE-FILLED PEN

Nucala Syringe
In Hospital

IN HOSPITAL
PRE-FILLED SYRINGE

Video guidance prefilled Pen

open

Video guidance prefilled Syringe

open

Need more information?

Efficacy

Efficacy

Eos and Moa

Eosinophils & Moa

Dosing and Administration

Dosing & Administration

**SOC defined as daily mometasone furoate nasal spray in addition to saline nasal irrigations and courses of systemic corticosteroids and/or antibiotics as required.1,2
CI, confidence interval; CRSwNP, chronic rhinosinusitis with nasal polyps; MOA, mode of action; HR, hazard ratio; IL, interleukin; LS, least squares; SC, subcutaneous; SNOT-22, sino-nasal outcome test (22-item); SOC, standard of care; VAS, visual analogue scale.

References

  1. Han JK et al. Lancet Respir Med.2021;9:1141-1153
  2. Han JK et al. Lancet Respir Med.2021;9:1141-1153 (Supplementary)
  3. Nucala preparatomtale

Nucala is a trademark of the GSK group of companies

PM-NO-MPL-WCNT-230002 November 2024